DCTD Functional Genomics

DCTD功能基因组学

基本信息

批准号：
8654748
负责人：
DAVID HEIMBROOK
金额：
$ 89.24万
依托单位：
LEIDOS BIOMEDICAL RESEARCH, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-26 至 2018-09-25
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8654748
关键词：
Alkaloids Althaea American Association of Cancer Research Animals Area Biological Assay Blood specimen Businesses CCAAT-Enhancer-Binding Proteins CCR CHEK2 gene CHES1 gene Cell Cycle Cell Line Cell surface Cells Cessation of life Clinic Clinical Collaborations Cooperative Research and Development Agreement DNA Damage DNA Repair Data Databases Development Developmental Therapeutics Program Drug Combinations Drug effect disorder European Organization for Research and Treatment of Cancer Evaluation Studies Extramural Activities Gene Expression Genes Genomics Histone Deacetylase Inhibitor Histones Human In Vitro Kinesin Laboratories Laboratory Animals Lead Legal patent Measures Methods Mitosis Modeling Molecular Profiling Molecular Target Oligonucleotide Microarrays PXD101 Paclitaxel Pathway interactions Patients Pattern Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Phase Play Preclinical Drug Development Proteins Publishing RNA RNA Interference Reporter Genes Research Support Resources Role Sampling Scientist Staging Techniques Technology Testing Therapy Evaluation Time Topoisomerase Topotecan Tretinoin Tumor Cell Line Up-Regulation Whole Blood Xenograft procedure analog aurora-A kinase base blood treatment cancer diagnosis cancer therapy cytotoxicity drug development drug discovery functional genomics in vivo inhibitor/antagonist insight marine natural product meetings melanoma neutrophil novel pre-clinical programs protein expression research study response screening tool tumor vacuolar H+-ATPase

项目摘要

This project is a major part of the Developmental Therapeutics Program drug discovery and development program within the Division of Cancer Treatment and Diagnosis. The emphasis is on preclinical drug discovery and preclinical drug development. LABORATORY OF FUNCTIONAL GENOMICS (LFG) The Laboratory of Functional Genomics (LFG) provides dedicated research support for the Screening Technologies Branch (STB), Developmental Therapeutics Program (DTP), drug discovery and development effort. Genomic techniques, including oligonucleotide microarrays, TaqMan(R) real-time PCR, reporter gene assays, mutiplexing gene assays, and RNAi are used as tools to determine the role of specific genes in the mechanisms of drug action. These methods have provided an important resource to probe for preliminary insights into mechanism of action of novel agents, or detailed analyses with preclinical drugs at a more advanced stage. The laboratory offers a resource for small businesses or extra- and intramural scientists to collaborate in an effort to bring new drugs to the clinic. Moreover, the expertise gained in this area has allowed the laboratory to play a critical role in proposing a large-scale project centered on gene profiling of drug responses in the NCI-60 cell line screen. In addition, the LFG provides preclinical, in vitro drug combination studies for evaluation of possible desirable or undesirable interactions for potential clinical drug combinations, as requested by DTP or the Clinical Therapy Evaluation Program (CTEP).

该项目是癌症治疗和诊断部门内发展治疗计划药物发现和开发计划的主要部分。重点是临床前药物发现和临床前药物开发。功能基因组学实验室 (LFG) 功能基因组学实验室 (LFG) 为筛选技术部门 (STB)、发展治疗计划 (DTP)、药物发现和开发工作提供专门的研究支持。基因组技术，包括寡核苷酸微阵列、TaqMan实时PCR、报告基因检测、多重基因检测和RNAi，被用作确定特定基因在药物作用机制中的作用的工具。这些方法为初步了解新药的作用机制或在更高级阶段对临床前药物进行详细分析提供了重要的资源。该实验室为小型企业或校外和校内科学家提供了合作资源，努力将新药推向临床。此外，在该领域获得的专业知识使该实验室能够在提出一个以 NCI-60 细胞系筛选中药物反应的基因分析为中心的大型项目中发挥关键作用。此外，LFG 还根据 DTP 或临床治疗评估计划 (CTEP) 的要求，提供临床前体外药物组合研究，以评估潜在临床药物组合可能出现的理想或不良相互作用。